Ideally, quality assessment using the QIs would require a specific and dedicated survey, but the organization of such a survey would necessitate considerable time and expense. Therefore, the idea of applying QIs to existing databases is appealing. Indeed, it remains to be determined whether the QI developed by the ACCA can be assessed from existing registries, how they are related to long-term survival, and whether it is possible to use the QIs to perform center benchmarking. To address this need, we assessed the rates of implementation of the ACCA QIs in the French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 and 2010, we investigated the association between these QIs and 3-year mortality, and we categorized centers according to the opportunity-based composite QI.
Methods

Setting and Design
Data for this population-based cohort study were extracted from 2 nationwide French registries, conducted 5 years apart, namely FAST-MI 2005 (NCT00673036) 12 and FAST-MI 2010 (NCT01237418). 13 Briefly, the primary objectives of the FAST-MI registries were to evaluate the characteristics, management, and outcomes of AMI patients, as seen in routine clinical practice, on a nationwide scale. Both registries consecutively included patients with AMI admitted to a coronary or intensive care unit within 48 hours of symptom onset over a 1-month period (October to November 2005 and 2010). For patients with diabetes, the inclusion period lasted 2 months in 2005. Data on baseline characteristics, including demographics, risk and medical history, previous use of cardiac procedures (including timing of percutaneous coronary intervention), use of medications (including previous, acute, and discharge treatments), and biological variables were collected, as previously described. [12] [13] [14] [15] [16] For both surveys, centralized follow-up was performed by the French Society of Cardiology. Dedicated research technicians contacted both physicians and patients after checking the patients' vital status in municipal registers. All institutions admitting patients for AMI were invited to participate, including university teaching hospitals, community hospitals, and private clinics. The study was conducted in accordance with the guidelines on good clinical practice and French legislation. Both registries were approved by Committees for the Protection of Human Subjects in Biomedical Research. All patients provided written informed consent. The comparison between FAST-MI 2005 and 2010 was used to assess whether the degree of application of the QIs changed over time.
Assessment of Variables and QIs
For each patient, data fields were identified that would enable the calculation of the 20 QIs. For each QI, the denominator (number and proportion of patients in whom the QI is applicable) and the numerator (number and percent of patients who satisfy the QI, among those applicable) were calculated using the most appropriate variables. QIs were not measured in patients who died in hospital. The QI were classified into one of 4 categories, namely, (1) QIs that could be assessed directly from existing variables; (2) QIs calculated from ≥2 variables; (3) QIs estimated after extrapolation or use of a proxy; and (4) QIs that could not be assessed using existing data. For each patient, the opportunity-based CQI was calculated based on the number of times particular care processes were performed (numerator) divided by the number of opportunities the patient had to receive that process or the number of opportunities the hospital had to provide the process, as appropriate (denominator). The opportunitybased CQI is presented as mean±standard deviation (SD).
The all-or-none CQI was calculated as follows: -In patients with a left ventricular ejection fraction (LVEF) >40% and no evidence of heart failure: as the proportion of patients fulfilling all 3 score elements, namely, low-dose aspirin, P2Y 12 inhibitor, and high-intensity statins. -Adequate P2Y 12 inhibition was defined according to the labeling of the drugs and European Society of Cardiology guidelines.
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-In patients with an LVEF ≤40% and clinical evidence of heart failure: as the proportion of patients fulfilling all 5 score elements, namely, low dose aspirin, P2Y 12 inhibitor, high-intensity statins, angiotensin-converting enzyme inhibitor (or angiotensin-receptor blocker) and β-blockers. To estimate the adjusted mortality risk, we calculated each patient's GRACE risk score for 6-month mortality from existing data, according to the initial description of the GRACE risk score. 18 Then, we used categories of the GRACE risk score defined by deciles of the score.
The number of patients included in the registries was used as proxy for the volume of activity of each center.
Statistical Analysis
Baseline characteristics for the study population are reported as number (percentage) for categorical data and medians (interquartile range) or mean±SD for continuous non-normally and normally distributed data, respectively. QIs are presented as denominator (patients eligible for the QI) and numerator (number of patients who presented the QI criterion among those eligible). The opportunitybased composite QI was split into 4 quartiles, and into 3 categories, in keeping with recognized cutoffs, namely, 0% to 40%, 40% to 80%, and >80%. 19, 20 To estimate the strength of the association between QIs and long-term mortality, we fitted a Kaplan-Meier survival curve for the 4 quartiles of the opportunity-based CQI. Multivariate survival analysis was performed using Cox's proportional hazards model for 3-year survival, adjusted for baseline characteristics, risk factors, type of myocardial infarction (ST-segment-elevation myocardial infarction [STEMI] versus non-STEMI), deciles of the GRACE score, biological variables at admission, volume of activity of the center, availability of coronary angioplasty on site, and period (2005 
WHAT IS KNOWN
• Evaluating the quality of care in acute myocardial infarction is difficult because it is a multifactorial process that cannot be assessed solely on the basis of patient outcomes.
• The Acute Cardiovascular Care Association of the European Society of Cardiology recently defined a set of QIs for the management of acute myocardial infarction.
WHAT THE STUDY ADDS
• In 2 nationwide French registries, some QIs could not be assessed in either cohort because of treatment nonavailability or data not recorded because the registries were not specifically designed for QI assessment.
• Seven individual QIs were associated with 3-year survival, and there was a significant and gradual association between survival and increasing categories of the composite QI.
• Using the composite QI for center benchmarking was able to distinguish centers with high, average, and low quality of care.
or 2010 cohort). Results are presented as hazard ratios with 95% confidence intervals (CI).
To estimate the variability of the QIs across centers, we calculated the mean (83% CI) of the opportunity-based CQI in all centers that included >20 myocardial infarction patients in the registry. To classify these centers as low, intermediate, or high quality, the mean and 83% CI are displayed for each center in 2005 and 2010 separately. Centers can be considered significantly different at the 5% level if their CIs do not overlap.
Analyses were performed using SAS software, version 9.4 (SAS Institute Inc, Cary, NC). All tests were 2 sided, and a P value <0.05 was considered significant. Table 1 . Acute and discharge treatments, as well as mortality rates, are presented in Table 2 .
Results
Assessment of QIs From FAST-MI 2005 and 2010
Domain 1: Center Organization
Despite prospective data collection regarding the type of center (academic, public nonacademic, or private for-profit), equipment, staff, and volume of activity, no information was prospectively recorded regarding the existence of a network organization or regarding prehospital interpretation of ECG or cath laboratory activation (Table 3 ). Time to reperfusion was available in >80% of STEMI patients. Finally, because participation in the FAST-MI registry is on a voluntary basis, all FAST-MI centers fulfilled the QI pertaining to voluntary participation in registries to assess quality of care.
Domain 2: Reperfusion/Invasive Strategy
The specific times between onset of pain and reperfusion were available in >80% of the cases. 21 Eligibility for reperfusion was determined according to the time between symptoms (<12 hours) and first medical contact in STEMI patients. Only 35% of the population was eligible for the QIs related to times to reperfusion with primary percutaneous coronary intervention (PCI), and this proportion was 40% for the assessment of timely reperfusion, considering either fibrinolysis or primary PCI. Only patients admitted in PCI-capable centers could be assessed because the door-in-door-out times for transferred patients were not recorded. The time to balloon was used as a proxy for the time to arterial access. Specifically, we were able to determine eligibility for reperfusion in all patients, and the rates of reperfusion among eligible patients were 71% and 81% in 2005 and 2010, respectively. The time from first medical contact to reperfusion was available in all patients treated with fibrinolysis (first medical contact to needle) and in 100% and 91% of patients treated by primary PCI in 2005 and 2010, respectively. The rate of non-STEMI patients submitted to invasive strategy within 72 hours of presentation was 79% in 2005 and 92% in 2010. 
Temporal Changes in QI Between 2005 and 2010
Among the QIs that were measurable in both cohorts, we observed higher rates of reperfusion and invasive strategy, more frequent recording of LVEF, higher rates of dual antiplatelet therapy and high-intensity statins at discharge, and greater use of β-blockers and angiotensin-converting enzyme inhibitor/angiotensin-receptor blockers in patients with LVEF<40%. As a result, the opportunity-based composite QI was higher in 2010 than in 2005.
Association Between the QIs and Mortality
Multivariable analysis showed an association between most of the individual QIs assessed and 3-year mortality (Figure 1) , adjusted for the GRACE risk score, type of myocardial infarction, year of admission, and type of center (with versus without PCI on site). The Kaplan-Meier survival curves showed that there were significant differences between quartiles of the opportunity-based CQI (Figure 2) . Using the Cox model, adjusted for GRACE risk score (in deciles), type of myocardial infarction, PCI capability, and cohort, there was a decrease in mortality with increasing categories of the CQI; hazard ratio, 0.19 (95% CI, 0.13-0.28) for >80% versus ≤40%; hazard ratio, 0.38 (95% CI, 0.32-0.46) for 40% to 80% versus ≤40% (Figure 3 ).
Center Benchmarking
The mean (83% CI) of the CQI was used to perform center benchmarking and was possible among centers with >20 patients included, that is, only 26% to 30% of the centers (n=58 in 2005 and n=69 in 2010; Figure 4 ). 
Discussion
This study shows that 80% of the QIs developed by the ACCA for the treatment of AMI can be extracted from existing registries, and relatively minor changes in the registry design could improve this rate. The application of the opportunity-based CQI is mainly limited by the number of patients included per center. The CQI is related to survival and makes it possible to distinguish quality levels between centers. These results could have an impact on the use, diffusion, and assessment of these QIs and influence the design of future registries, as well as influencing any future upgrades of the QIs. The QIs developed by the ACCA were defined with the primary aim of improving quality, but also with a view to multinational assessment. Ideally, this would require a specific and dedicated survey, but considering the cost and complexity of such a survey at a European level, and the number of already existing high-quality national databases in Europe, the idea of using existing databases is appealing. Our results show that several QIs can be measured directly, whereas certain others can only be assessed after transformation or extrapolation of existing variables. Finally, some QIs could not be measured at all either because the necessary variables (or even a proxy thereof) were lacking or because the drugs or strategies under evaluation were not available at the time of data recording. It would be feasible to improve the possibility of assessing QIs from existing registries at low cost and with minimum effort, for example, for variables such as center organization, numeric GRACE or Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines scores, or statin intensity. The required variables could easily be captured with a simple data field update. Conversely, although delivery of timely reperfusion is a widely used and undisputed metric for assessing quality of care, assessing the different times for . ESC-ACCA Quality Indicators for AMI reperfusion and pathways is complex and suffers from many limitations. An accurate time of onset of symptoms or time of first medical contact is often either lacking or unreliable, and a precise definition and standardization of how these times are measured is mandatory, as proposed in the American College of Cardiology/American Heart Association statement on performance measures and reperfusion therapy. 22 As shown in our study, because QIs are based on the application of recent guidelines, including the use of new drugs or strategies, they often cannot be applied in ongoing or old registries, unless only recently admitted patients are selected. Thus, the FAST-MI 2005 database cannot be used in the same way as the FAST-MI 2010 database, resulting in a debatable and, maybe, artificial improvement in quality, partially explained by the changes in guidelines and the availability of drugs and strategies. Finally, recording exceptions in QIs 23 in regular registries, such as medical reasons (eg, contraindications, nonindications, intolerance), patient-related reasons (eg, patient preference, social, or economic reasons), and system-related reasons (eg, insurance coverage or availability of drugs) would be more difficult to implement. The increase in the rate of application of QIs between 2005 and 2010 could reflect a genuine increase in quality of care, but could also reflect a difference in the risk profile of patients between the 2 cohorts. Although there was no change in the average age of non-STEMI patients, 24 the age of STEMI patients has declined over time in France. 21 This change is explained by the overall decline in the incidence of AMI in France, which mainly affects patients over 65 years of age, thus decreasing the mean age of STEMI patients. 25 The significant link between long-term survival and most of the individual QIs, as well as the opportunity-based CQI, is an important finding because firm evidence of the impact of quality of care on mortality is sparse. In our study, this relation is significant, even after adjustment for deciles of the GRACE risk score, year of admission, type of AMI, and PCI capability of the admitting center. We cannot exclude the possibility that other potential confounders may exist, but from the present data, the reality of the impact of quality on survival seems plausible. This impact on survival is an additional argument in favor of better acceptability by physicians of the routine assessment of the quality of care. Furthermore, wider use of QIs for assessment and benchmarking of quality of care could encourage better compliance with these specific processes of care.
The composite QI was used to perform center benchmarking. Although this method seems adequate, it suffers from some limitations, mainly related to the number of patients included in the registry. Only 25% to 30% of the centers were considered for the benchmarking because of a limited number of patients included by each center. This is explained in our study by the limited inclusion period (1 month) of the FAST-MI registries. Because quality issues are more likely to be observed in low-volume centers, 26 a prolongation of the inclusion period to reach a minimum of 20 patients per center is mandatory to allow classification of all centers. Because the relation between volume of activity and quality of care is documented, 26 the assessment of quality in low-volume centers is important. Nevertheless, it is likely that this limitation is not present for other large European registries where there is no predetermined inclusion period. Finally, because participation in the FAST-MI registries was on a voluntary basis and approximately one quarter to one third of centers in France declined to participate, we cannot exclude the possibility of a selection bias in the measure of quality of care.
The all-or-none CQI seems more difficult to interpret because it was calculated from only 3 items in patients without LV dysfunction and would need large cohorts to be measured among patients with impaired LVEF.
Finally, our results have the potential to affect the update of the definition of QIs. Future revisions of the QI set will take into account not only the changes necessary to remain aligned with current guidelines, but also the challenges of assessing QIs as seen in our study. From our results, no QI had a rate of measurement >90%, showing that there is still room for improvement and, therefore, no need for withdrawal. Conversely, the rate of several QIs was low, such as the use of fondaparinux, suggesting there may be bias in its assessment in addition to lack of compliance with guidelines. The guidelines also leave the door open for alternative strategies, such as the use of low-dose enoxaparin, which may also contribute to keeping the rate of use of fondaparinux relatively low. Based on these findings, an update of this particular QI could be envisaged. The 2 QIs for patients with impaired LVEF also have several limitations, such as the low proportion of cases concerned (15% to 17% of the patients) and the need to record all potential contraindications, which cannot be extracted from current registries.
Conclusions
The application of the QI set developed by the ACCA to the FAST-MI 2005 and 2010 registries was possible for 12/17 individual QIs plus the composite indicators, covering different domains, such as reperfusion and invasive strategy, risk assessment, antithrombotic treatment, and secondary prevention. The opportunity-based composite QI calculated from existing variables was found to be significantly associated with adjusted mortality and had the capacity to distinguish centers with high, average, and low quality of care. These results may have an impact on the design of future registries and on the update of the ACCA QIs.
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